Results 231 to 240 of about 41,944 (264)

Olaparib

Reactions Weekly, 2018
Olaparib (Lynparza [AstraZeneca, Cambridge, UK], formerly referred to as AZD2281 or KU0059436) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor. It is rationally designed to act as a competitive inhibitor of NAD+ at the catalytic site of PARP1 and PARP2, both members of the PARP family of enzymes that are central to the repair of DNA single ...
Sylvia, Bochum, Stephanie, Berger, Uwe M, Martens   +2 more
  +6 more sources

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Annals of Oncology, 2023
BACKGROUND In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line ...
I. Ray-Coquard, A. Leary, S. Pignata, C. Cropet, A. González-Martín, C. Marth, S. Nagao, I. Vergote, N. Colombo, J. Mäenpää, F. Selle, J. Sehouli, D. Lorusso, E. G. Alía, G. Bogner, H. Yoshida, C. Lefeuvre-Plesse, P. Buderath, A. Mosconi, A. Lortholary, A. Burges, J. Medioni, A. El-Balat, M. Rodrigues, T. Park-Simon, C. Dubot, D. Denschlag, B. You, E. Pujade-Lauraine, P. Harter   +29 more
exaly   +2 more sources

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

New England Journal of Medicine, 2019
BACKGROUND Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a BRCA mutation.
Isabelle Ray-Coquard, Sandro Pignata, Keiichi Fujiwara   +2 more
exaly   +2 more sources

Olaparib

Reactions Weekly, 2023
  +12 more sources

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.

NEJM Evidence, 2022
Abiraterone and Olaparib for Metastatic Prostate CancerPatients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair gene mutation status, received either abiraterone and olaparib or abiraterone and placebo ...
N. Clarke, A. Armstrong, A. Thiery-Vuillemin, M. Oya, N. Shore, E. Loredo, G. Procopio, Juliana de Menezes, G. Girotto, Ç. Arslan, N. Mehra, F. Parnis, E. Brown, F. Schlürmann, J. Joung, M. Sugimoto, J. Virizuela, U. Emmenegger, J. Navrátil, G. Buchschacher, C. Poehlein, E. Harrington, C. Desai, Jinyu Kang, F. Saad   +24 more
semanticscholar   +1 more source

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Annals of Oncology, 2019
Background In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1 and/or BRCA2 mutation (BRCAm) and human epidermal growth factor ...
Mark E Robson, Pierfranco Conté, Elżbieta Senkus   +2 more
exaly   +2 more sources

OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

European Journal of Cancer, 2023
Background: In the Phase III OlympiAD study, olaparib significantly prolonged progression-free survival versus chemotherapy treatment of physician’s choice (TPC) in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer (mBC)
M. Robson, S. Im, E. Senkus, Bing-he Xu, S. Domchek, N. Masuda, S. Delaloge, N. Tung, A. Armstrong, M. Dymond, A. Fielding, A. Allen, P. Conte   +12 more
semanticscholar   +1 more source

Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).

Clinical Cancer Research
PURPOSE Deleterious germline/somatic homologous recombination-repair mutations (HRRm) are present in ~25% of metastatic castration resistant prostate cancer (mCRPC) patients. Preclinically, PARP-Inhibition demonstrated synergism with ARP-targeted therapy.
M. Hussain, Masha Kocherginsky, N. Agarwal, N. Adra, Jingsong Zhang, C. Paller, J. Picus, Z. Reichert, R. Szmulewitz, S. Tagawa, Timothy M. Kuzel, Latifa A Bazzi, S. Daignault-Newton, Y. Whang, R. Dreicer, Ryan D Stephenson, Matthew B. Rettig, D. Shevrin, Travis Gerke, A. Chinnaiyan, E. Antonarakis   +20 more
semanticscholar   +1 more source

Olaparib

Reactions Weekly, 2019
  +6 more sources

Olaparib

Reactions Weekly, 2022
  +4 more sources